Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
AML clinical trials: early stage vs. relapse/refractory patients
An update on two trials evaluating venetoclax in subsets of CLL
Factors to consider when choosing treatment for relapsed multiple myeloma patients
A follow-up from the CASTOR trial evaluating daratumumab with bortezomib for the treatment of MM